Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733827 | 0.93 | GRM2 (0.50) | GRM2PGRNR3C1CNR1CNR2 | |
| SCHEMBL6727498 | 0.90 | GRM2 (0.62) | GRM2PGRNR3C1CNR1CNR2 | |
| SCHEMBL6734087 | 0.88 | GRM2 (0.67) | GRM2PGRNR3C1 | |
| SCHEMBL6732511 | 0.88 | GRM2 (0.72) | GRM2 | |
| SCHEMBL6735185 | 0.85 | GRM2 (0.56) | GRM2PGRNR3C1 | |
| SCHEMBL6734022 | 0.83 | GRM2 (0.76) | GRM2PGRNR3C1 | |
| SCHEMBL6733534 | 0.83 | GRM2 (0.62) | GRM2PGR | |
| SCHEMBL6730872 | 0.82 | GRM2 (0.47) | GRM2LMNA | |
| SCHEMBL6727795 | 0.81 | GRM2 (0.66) | GRM2 | |
| SCHEMBL6738944 | 0.80 | GRM2 (0.55) | GRM2PGRNR3C1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6800651-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | GRM2 3/4885PGR 697/4885NR3C1 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.